CLINICAL TRIAL: CMV-SPECIFIC CELLULAR IMMUNITY IN RECIPIENTS OF ALLOGENIC BONE M

临床试验：同种异体骨 M 接受者的 CMV 特异性细胞免疫

• 批准号: 7716632
• 负责人: John A Zaia
• 金额: $ 5.29万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-20 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716632
• 关键词: Allogenic; Binding; Biological Assay; CTL assay; Cells; Cellular Immunity; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Cytomegalovirus; Disease; Funding; Goals; Grant; Immune; Immunity; Infection; Institution; Lymphocyte; Measures; Peptides; Persons; Purpose; Research; Research Personnel; Resources; Source; Testing; Transplant Recipients; Transplantation; Tube; United States National Institutes of Health; Virus; Work; bone; day; killings

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine whether an experimental test for immunity to CMV can determine when immunity to this virus is present after transplantation and whether the test can predict that a person is protected from serious CMV infections after transplantation. Participation in this study is expected to last approximately 5 days for donors, and for 1 year for transplant recipients. An ability to protect yourself from CMV infection is called CMV-specific cellular immunity. This immunity is among the most important factors that determine whether you will get a serious CMV infection after transplantation. There are various ways to measure this immunity. One of the most important ways is to determine if your lymphocytes (cell immunity) can kill CMV-infected cells. This is called a CTL assay. It is known that persons who develop good CTL levels have protection against severe CMV infection after transplantation. The CTL test is difficult to perform and an experimental test has been developed to try to predict whether or not a person is immune. This experimental test is called the HLA-peptide tetramer binding assay (TBA), and, although it is known that the TBA works well in the test tube, it has not yet been evaluated in persons undergoing transplantation. The goals of this study are to determine how best to perform the TBA test for transplant patients and to determine whether or not your TBA levels predict whether you will be protected from CMV infection or disease after transplant. Another goal of this study will be to determine what effects your treatments have on your levels of CMV immunity as measured by this experimental test and other tests of immunity.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的目的是确定对CMV免疫的实验测试是否可以确定在移植后何时存在对该病毒的免疫力，以及该测试是否可以预测一个人在移植后受到严重的CMV感染。预计捐助者将持续大约5天，而移植受者则将持续1年。 保护自己免受CMV感染的能力称为CMV特异性细胞免疫。这种免疫力是决定您在移植后是否会感染严重的CMV感染的最重要因素之一。有多种衡量这种免疫力的方法。最重要的方法之一是确定您的淋巴细胞（细胞免疫）是否可以杀死CMV感染的细胞。这称为CTL分析。众所周知，发展良好的CTL水平的人可以保护移植后严重的CMV感染。 CTL测试难以执行，并且已经开发了实验测试来试图预测一个人是否免疫。该实验测试称为HLA肽四聚体结合测定法（TBA），尽管众所周知，TBA在试管中效果很好，但尚未对接受移植的人进行评估。这项研究的目标是确定如何最好地为移植患者进行TBA测试，并确定您的TBA水平是否预测移植后是否会保护您免受CMV感染或疾病的保护。这项研究的另一个目标是确定您的治疗对您的CMV免疫水平的影响，如该实验测试和其他免疫测试所衡量。